Report: OTC Reforms Costly For Buy Side
Buy-side firms and other end users will face skyrocketing reporting and systems costs if they are caught up in over-the-counter derivatives regulation meant primarily for liquidity providers, according to a report from Aite Group.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts
